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A B S T R A C T
Introduction: Treatment of paediatric heart failure is based on paradigms extensively tested in the adult popu-
lation assuming similar underlying pathophysiological mechanisms. Angiotensin converting enzyme inhibitors
(ACEI) like enalapril are one of the cornerstones of treatment and commonly used oﬀ-label in children. Dose
recommendations have been extrapolated from adult experience, but the relationship between dose and phar-
macokinetics (PK) in (young) children is insuﬃciently studied. Furthermore, appropriate paediatric formulations
are lacking. Within the European collaborative project LENA, a novel formulation of enalapril orodispersible
minitablets (ODMT), suitable for paediatric administration, will be tested in (young) children with heart failure
due to either dilated cardiomyopathy or congenital heart disease in two pharmacokinetic bridging studies.
Paediatric PK data of enalapril and its active metabolite enalaprilat will be obtained. In a follow-up study, the
safety of enalapril ODMTs will be demonstrated in patients on long-term treatment of up to 10 months.
Furthermore, additional information about pharmacodynamics (PD) and ODMT acceptability will be collected in
all three studies.
Methods and Analysis: Phase II/III, open-label, multicentre study. Children with dilated cardiomyopathy (DCM)
(n=25; 1 month to less than 12 years) or congenital heart disease (CHD) (n= 60; 0 to less than 6 years)
requiring or already on ACEI will be included. Exclusion criteria include severe heart failure precluding ACEI
use, hypotension, renal impairment, hypersensitivity to ACEI. For those naïve to ACEI up-titration to an optimal
dose will be performed, those already on ACEI will be switched to an expected equivalent dose of enalapril
ODMT and optimised. In the ﬁrst 8 weeks of treatment, a PK proﬁle will be obtained at the ﬁrst dose (ACEI naïve
patients) or when an optimal dose is reached. Furthermore, population PK will be done with concentrations
detected over the whole treatment period. PD and safety data will be obtained at least at 2-weeks intervals.
Subsequently, an intended number of 85 patients will be followed-up up to 10 months to demonstrate long-term
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safety, based on the occurrence of (severe) adverse events and monitoring of vital signs and renal function.
Ethics and dissemination: Clinical Trial Authorisation and a favourable ethics committee opinion were obtained
in all ﬁve participating countries. Results of the studies will be submitted for publication in a peer-reviewed
journal.
Trial registration numbers: EudraCT 2015-002335-17, EudraCT 2015-002396-18, EudraCT 2015-002397-21.
1. Introduction
Heart failure in children has been deﬁned as a clinical and patho-
physiologic syndrome resulting from ventricular dysfunction, volume,
or pressure overload, or a combination of these causes. Characteristic
signs and symptoms are poor growth, feeding diﬃculties, respiratory
distress, and fatigue. In line with the pathophysiology of heart failure in
adults, an elevation of numerous neuro-humoral and inﬂammatory
mediators, such as the renin-angiotensin-aldosterone system (RAAS)
and natriuretic peptides have been found in children [1,2]. Heart
failure in children has a variety of aetiologies, including congenital
heart disease (CHD) and cardiomyopathies [3].
More than 50% of paediatric patients have heart failure due to CHD,
with this aetiology being disproportionately high in the ﬁrst year of life
[4,5]. It is associated with ventricular dysfunction, volume or pressure
overload. Heart failure in paediatric patients with CHD has various
aetiologies and the risk of ventricular dysfunction depends on the
speciﬁc type of malformation [6].
Dilated cardiomyopathy (DCM) refers to a large group of hetero-
geneous myocardial disorders that are characterised by a decreased
systolic function, ventricular dilation and reduced cardiac output.
Clinical onset is most often seen in infancy and although it accounts for
only a small proportion of heart failure cases in children, it is particu-
larly relevant as it is the main indication for paediatric heart trans-
plantation [7].
To date, the pharmacological therapy of paediatric heart failure is
mainly informed by empirical evidence and data extrapolation from
studies in the adult population. Systematic dose-ﬁnding and long-term
safety studies in children have been hampered by methodological and
practical diﬃculties. Therefore, appropriate doses that are safe and
eﬃcacious in diﬀerent paediatric age groups are not well established.
Heart failure medications including angiotensin converting enzyme
(ACE) inhibitors have shown eﬃcacy in controlled randomised clinical
trials in adults with heart failure. ACE inhibitor (ACEI) therapy in adults
should be initiated at low doses followed by up-titration if lower doses
have been well tolerated. At optimal doses, ACE inhibitor therapy re-
duces symptoms and improves survival of adult heart failure patients.
Dose-limiting adverse events in adults include hypotension, worsening
renal function and hyperkalaemia [8].
Enalapril is an ACE inhibitor commonly administered oﬀ-label to
young children with heart failure using extemporaneous formulations.
It is not labelled for patients below the age of 6 (< 20 kg) in the EU [9].
The beneﬁcial eﬀects of enalapril are assumed to be similar to those in
adults with heart failure due to cardiomyopathy or coronary heart
disease, resulting from afterload reduction improving cardiac output
and preventing cardiac hypertrophy and remodelling, as well as long
term inhibition of salt and water retention [10,11]. The European
Medicine Agency Expert Group Meeting on Paediatric Heart Failure
considered enalapril a ﬁrst-line treatment for chronic heart failure in
children [12]. However, no age-appropriate and stable formulation
exists in Europe and paediatric pharmacokinetic (PK) and safety data
for any formulation is insuﬃcient. Pharmacodynamics (PD) and eﬃ-
cacy data for paediatric cardiac indications are limited [13–15].
This lack of age-appropriate formulations and data for paediatric
use in general led the EU to implement regulations to encourage the
development of medicines and age-appropriate formulations for chil-
dren and prioritised a list of oﬀ-patent paediatric medicinal products to
be studied, making them subsequently eligible for a Paediatric Use
Marketing Authorisation (PUMA).
The European collaborative project LENA (Labelling Enalapril from
Neonates up to Adolescents) aims to address these shortcomings and
provide a basis for a future PUMA of enalapril for children with heart
failure.
As part of the LENA project, a novel formulation of orodispersible
minitablets (ODMT) was developed, small sized tablets (2mm in dia-
meter), which rapidly dissolve upon contact with water or saliva, sui-
table for paediatric administration [16]. Subsequently, a bioequiva-
lence study in healthy adults was performed, showing comparable
relative pharmacokinetics and drug exposure of the new ODMT and a
standard tablet formulation [17].
This manuscript presents the protocols of two clinical phase II/III
prospective, open-label, multicentre PK bridging studies in children (1
month to less than 12 years of age) with heart failure due to DCM and
CHD and one common follow-up safety study for both populations.
Study patients will be treated with the newly developed ODMTs of
enalapril and systematically assessed for PK, PD [18–22], clinical
parameters as well as acceptability and palatability. Due to strongly
established eﬃcacy of enalapril in adult heart failure and the similarity
of the pathophysiology of heart failure in adult and paediatric patients,
the Paediatric Committee (PDCO) of the European Medicines Agency
(EMA) agreed that PK bridging instead of proof of eﬃcacy would pro-
vide an adequate demonstration of treatment suitability of the newly
developed enalapril ODMTs in this population. Moreover, the studies
will collect safety data over 8 weeks. Subsequently, patients will be
included in an open-label, multicentre 10 months follow-up safety
study. This will allow for a systematic collection of safety data in
paediatric patients under stable optimal dose or no longer under en-
alapril ODMT treatment who have received at least 3 days of ODMT
treatment but then stopped.
In a pharmacogenomics and metabolomics sub-study, we aim to
study the metabolite proﬁle of children before and after enalapril
therapy, as well as the genes that determine enalapril disposition and
eﬀect, for better understanding the underlying disease and the response
to enalapril therapy in our population. Several single-nucleotide poly-
morphisms (SNPs) have been studied in relation to enalapril PK and PD
in adults, with some showing promise to individualize enalapril therapy
[23].
2. Methods and analysis
2.1. Study design
This manuscript describes the design of two phase II/III prospective,
open-label, multicentre PK bridging studies with exploratory PD as-
sessments. Twenty-ﬁve children (1 month to less than 12 years of age)
with heart failure due to DCM (EudraCT 2015-002335-17) and 60
children (up to less than 6 years of age) with heart failure due to CHD
(EudraCT 2015-002396-18) will be treated with newly developed
ODMTs of enalapril. A minimum of 37 infants (0 to less than 12
months) must be included.
Additionally, the manuscript presents the protocol of a phase II/III
prospective, open-label, safety follow-up study (EudraCT 2015-002397-
21) in infants and children with heart failure previously enrolled in the
two PK studies, under stable optimal dose or no longer under enalapril
ODMT treatment, with exploratory PD assessment in all children and
PK assessments in children under ODMT treatment.
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2.2. Study objectives
The primary objective of the pharmacokinetic bridging studies is to
obtain paediatric PK data of enalapril and its active metabolite en-
alaprilat in these children in order to characterise the dose exposure in
the paediatric population with DCM or CHD. The secondary study ob-
jectives are:
- to demonstrate safety, in particular renal safety, of enalapril ODMTs
in children with DCM/CHD,
- to characterise the dose/safety relationship from a starting dose to
an optimal maintenance dose,
- to explore the dose-exposure-response relationship with PD para-
meters in the paediatric population with DCM/CHD,
- to investigate the left ventricular shortening fraction (SF) by echo-
cardiography,
- to investigate the acceptability and palatability of enalapril ODMTs
in the paediatric population with DCM/CHD.
The objectives of the pharmacogenomics and metabolomics sub-
study are to explore the relationship between selected SNPs and en-
alapril PK and PD, and to explore the metabolite proﬁle in children
receiving enalapril ODMT. A comparison of the metabolite proﬁle be-
fore and after the start of enalapril, as well as between patients with
DCM and patients with CHD, is planned.
The primary objective of the follow-up safety study is to demon-
strate the safety of enalapril ODMTs. The secondary objectives are:
- to describe the acceptability and palatability of enalapril ODMTs,
- to collect additional information about PK and PD of enalapril
ODMTs during long-term treatment.
The studies were designed by the LENA consortium. The studies are
being performed at seven sites in ﬁve countries in Europe. The phar-
macokinetic bridging studies started in January 2016, the follow-up
study started in March 2016. The LENA project is planned to be com-
pleted by April 2019. The active treatment period per participant in the
pharmacokinetic bridging studies will be a minimum of three days up to
eight weeks; the observation period is eight weeks. The follow-up
period per participant will be up to 10 months.
2.3. Study population
Inclusion criteria: Patients fulﬁlling the following inclusion criteria
can be enrolled in the pharmacokinetic bridging studies:
- Diagnosis of heart failure due to CHD requiring after load reduction
by drug therapy.
or
- Diagnosis of DCM presenting with LV end-diastolic dimension ˃P95
and/or LV shortening fraction ˂25% in patients, resulting from
diﬀerent types of underlying cardiac disease with signs of decreased
systolic LV function, and without ACE inhibitor treatment; patients
with ACE inhibitor pre-treatment must have documented evidence
of having fulﬁlled these criteria before start of the ACE inhibitor
therapy.
- Male and female patients.
- Age 1 month to less than 12 years for patients with DCM
- Age from birth to less than 6 years for patients with CHD
- Weight greater than 2.5 kg
- Subjects may be naïve to ACE inhibitors.
- Subjects already on ACE inhibitor willing to switch to enalapril
ODMTs.
- Written informed consent from parent(s)/legal representative and
assent from the patient according to national legislation and as far as
achievable from the child.
Exclusion criteria: Patients fulﬁlling any of the following criteria
will be excluded:
- Severe heart failure and/or end stage heart failure precluding in-
troduction or continuation of ACE inhibitor.
- Too low blood pressure, e.g. less than P5 for age.
- Restrictive and hypertrophic cardiomyopathies.
- Obstructive valvular disease (peak echocardiographic gradient more
than 30mm Hg).
- Uncorrected severe peripheral stenosis of large arteries including
severe coarctation of the aorta.
- Severe renal impairment with serum creatinine above 2x ULN
(Upper Limit of Normal) according to the hospital's test metho-
dology.
- History of angioedema.
- Hypersensitivity to ACE inhibitor.
- Concomitant medication:
o Dual ACE inhibitor therapy
o Renin inhibitors
o Angiotensin II antagonists
o NSAIDs except acetylsalicylic acid only for antiplatelet therapy
- Already enrolled in an interventional trial with an investigational
drug, unless no interference with the current study can be shown.
2.4. Inclusion criteria for follow-up
Patients fulﬁlling the following inclusion criteria can be enrolled:
- Patients from the preceding pharmacokinetic bridging studies who
have been treated with enalapril ODMT and are still under ODMT
treatment.
- Patients from the preceding studies who have been treated for at
least 3 days with enalapril ODMT and are no longer under ODMT
treatment.
- Provided written informed consent by patient and/or parent(s)/
legal representative for participation in this follow-up safety study
and assent is received from the patient according to national legis-
lation and as far as achievable from the child.
Exclusion criteria for follow-up: As it is the aim of this follow-up
study to observe the safety of all patients exposed to enalapril ODMT
treatment, no additional exclusion criteria are deﬁned in this protocol.
However, adapted to the health situation of the patients, the in-
vestigators will decide whether planned study activities can be per-
formed.
2.5. Sample size
The number of patients to be included was previously agreed with
the PDCO of the EMA, to provide the best balance between a good
representation across the age cohorts where most age-related changes
in PK and PD are to be expected due to growth and maturation and
recruitment feasibility.
The study was designed to obtain paediatric PK data of enalapril
ODMTs in order to describe the dose-exposure in this population, as
well as safety data on the use of the IMP in paediatric patients. The
sample size was therefore determined taking into consideration these
key aims and based on literature PK values for enalapril in paediatric
patients and published safety data in paediatric patients treated with
enalapril. Only two small studies investigating the PK of enalapril in
paediatric heart failure patients have been published; 10 patients aged
from 6 weeks to 8 months [13] and 12 patients aged from 10 days to 6.5
years [14]. In contrast, enalapril PK was investigated in 40
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hypertension patients aged from 2 months to 15 years, with the eva-
luation of approximately 10 subjects in diﬀerent age sub-sets to assess
impact of age on the disposition of the drug and its metabolite en-
alaprilat [15]. Safety experience with enalapril in children is mainly
derived from a single clinical study in 110 hypertensive paediatric
patients aged 6–16 years [24]. The drug was generally well tolerated,
and twelve patients experienced 14 AEs, none of which included renal
failure, angioedema or hyperkalaemia. In contrast, post marketing data
on the use of the ACEIs enalapril and captopril in neonates and young
infants frequently report renal failure (in addition to hypotension) as an
AE. Retrospective analyses of AEs in term neonates and infants taking
ACEIs have estimated the rate of renal AEs to be between approxi-
mately 15 and 20% [25,26]. Hence, taking into consideration the PK
studies described above, and the need to ensure suﬃcient patient
numbers to investigate safety, a total of 100 patients were initially
planned. The number of patients per age sub-set were based upon the
known prevalence of DCM in these age groups. However, it was con-
sidered that the disposition of enalapril was unlikely to signiﬁcantly
diﬀer between paediatric DCM and CHD patients, and it would there-
fore be feasible to combine the PK/PD data generated from paediatric
patients with heart failure due to cardiomyopathy and congenital heart
disease for PK modelling and simulation.
According to the approved amendment to the Paediatric
Investigation Plan (PIP), the minimum number of evaluable patients
with DCM to be included across all age groups is 25. The required
minimum numbers per age group at the time of inclusion are 9 patients
below 12 months (the age range where PK data and safety data are most
needed), 8 patients between 12 months and below 6 years and 6 pa-
tients between 6 years and below 12 years. The number of evaluable
patients with CHD to be included across all age groups is 60 with a
minimum number of below 12 months of age is 37. Out of the total
number of DCM and CHD patients a sub-set of 10 patients each will be
envisaged for the age groups 0–3 months, 4–6 months and 7–12 months
respectively. In the follow up study, 40 patients below 12 months of age
at minimum need to be monitored during the treatment and at least 1
month after discontinuation of enalapril ODMT. At least 20 patients
recruited as neonates or infants in the preceding studies need to be
monitored for at least 6 months after ﬁrst enalapril ODMT adminis-
tration. Where possible, patients will be monitored for up to 12 months
after ﬁrst enalapril ODMT administration (10 months in this follow-up
safety study).
2.6. Study drug and dosing regimen
Enalapril will be administered orally as ODMTs (available in form of
0.25 and 1.0mg ODMTs). Patients who have been previously treated
with an ACE inhibitor will be treated with the same prescribed dose of
enalapril ODMT. Patients who are naïve to ACE inhibitors will be up-
titrated according to a deﬁned dose titration scheme based on adult
data extrapolated to children. Dose-titration aims at achieving optimal
eﬃcacy while avoiding adverse events. Daily doses will be increased in
1–7 days intervals, depending on the clinical needs, until the in-
dividually deﬁned optimal long-term dose is reached. Uptitration will
be subject to agreed stopping rules including sustained hypotension,
serum creatinine levels increasing to twofold the baseline level, and
potassium levels> 5.5 mmol/l. For the initial titration doses in very
small children (2.5 kg – max. 7 kg), the ODMT may be dispersed in
water according to a deﬁned application procedure via a syringe to
allow administration of smaller doses, if deemed appropriate by the
investigator.
In the follow-up study, all patients who will be under stable en-
alapril ODMT treatment at the end-of-study visit in the preceding study,
will continue their dosing regimen in this study. Dose adaptation may
be required during the maximum of 10 months study duration and will
be adapted according to the judgement of the investigator.
2.7. Outcomes and study procedures
The primary outcome of the pharmacokinetic bridging studies is the
bioavailability of enalapril and its active metabolite enalaprilat in
children with heart failure (area under the curve (AUC) within a dosing
interval of 12 h, Cmax and Tmax); descriptive PK investigation.
Fig. 1. Study design and sampling regimen. The full PK proﬁle (FPK) will be obtained at steady state in patients who have previously been treated with an ACE
inhibitor and at initial dose visit in ACE inhibitor naïve patients. Subsequently, trough levels (thin arrows) will be taken before each titration step and at least every
two weeks, combined with safety laboratory testing.
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The secondary outcomes are.
1. The bioavailability of enalapril and its active metabolite enalaprilat
in the diﬀerent age subsets (1 months to less than 12months, 12
months to less than 6 years, 6 years to less than 12 years) of the
paediatric population (AUC within a dosing interval of 12 h, Cmax
and Tmax); descriptive PK investigation.
2. Markers of the RAAS as exploratory PD investigation.
3. Brain natriuretic peptides (NT-proBNP).
4. Acceptability and palatability of the novel formulation.
5. Safety parameters including blood pressure and renal function.
6. Echocardiography (SF).
7. Rehospitalisation due to heart failure including the need for heart
transplantation or the institution of mechanical circulatory support.
8. Death due to worsening of the underlying disease.
9. PD and eﬃcacy endpoints analysis to diﬀerentiate high and low
output disease.
The outcome parameters of the pharmacogenomics and metabo-
lomics sub-study are selected SNPs in genes relevant for enalapril PK
(e.g. CES1, OATP1B1), PD and safety (e.g. angiotensinogen gene,
NR3C2), and metabolite proﬁle (untargeted and targeted). As currently
new platforms are being developed and new SNPs may emerge, the
exact choice of platforms, candidate genes and relevant SNPs will be
made at the time of analysis.
2.7.1. Study procedures – PK bridging studies with exploratory PD
assessments
The sampling regimen (Fig. 1) consists of one PK/PD proﬁle day
with blood sampling at up to 6 predeﬁned time points over up to 12 h
and single PK/PD sampling during titration, dose conﬁrmation and
study control visits every two weeks and at the end of the study after 8
weeks. The PK/PD proﬁle can be collected during initial dose visit or at
any study control visit, once an optimal dose is reached. PD includes
renin, angiotensin I, aldosterone, plasma renin activity as markers of
the RAAS. At the screening visit, inclusion and exclusion criteria will be
checked, demographic data (age, ethnicity) will be collected and the
medical history will be assessed. Echocardiography, ECG, full blood
count and measurement of NT-proBNP and body height will be per-
formed at the screening visit and the end-of-study visit.
Continuous blood pressure and heart rate measurements will be
performed every 30min for 8 h at initial dose, for 4 h at ﬁrst titration
visit and for 2 h as of the next titration visits. At all other visits, blood
pressure and heart rate will be measured as part of the routine safety
data assessment.
Renal safety laboratory tests (blood urea nitrogen, creatinine, and
potassium), urine analyses for evaluation of microalbuminuria, collec-
tion of adverse events (AEs) and adverse reactions (ARs) and con-
comitant medication, body weight measurement and physical ex-
amination will be performed at each visit. The Clinical Heart Failure
Score (modiﬁed Ross Score) will be calculated.
Acceptability and palatability assessments will be performed at the
initial dose visit, at a study control visit, preferably on day 28, and at
the end-of-study visit.
Blood sampling for the metabolomics sub-study will be performed at
screening visit and end-of-study visit. For genetic analysis a blood
sample will be collected at the end-of-study visit but can also be col-
lected any time during the study, as long as the total allowed blood
sampling volume is not exceeded.
2.7.2. Study procedures – safety follow-up study
The primary outcome of the follow-up safety study is the safety of
enalapril ODMTs in children with heart failure. Collection of informa-
tion on adverse events will take place at each visit. Study visits will take
place at day 0, month 1, 4, 7 and 10. The deﬁnition of (serious) AEs will
be according to the Medical Dictionary for Regulatory Activities
(MedDRA).
As in the preceding pharmacokinetic bridging studies, there are
several secondary study parameters including acceptability of enalapril
ODMTs, vital parameters, renal function and NT-proBNP, measured at
each study visit.
Clinical haematology parameters will be determined and a standard
ECG will be performed at the ﬁrst follow-up and the end of study visit.
In order to monitor potential eﬀects of ongoing or earlier adminis-
tration of enalapril ODMTs on the RAAS, markers of the RAAS will be
measured as part of PD sampling.
In addition, at each visit, a single blood sample will be collected to
measure the enalapril and enalaprilat plasma levels during long-term
treatment for PK analysis in patients under ongoing enalapril ODMT
treatment.
2.8. Early termination and follow-up
In case enalapril ODMT treatment is terminated early for whatever
reason, patient and parents will be invited to remain in the study until
the end-of-study visit of the follow-up study for safety supervision and
PD assessments. In case the patient or the parents want to terminate
study participation early, the end-of-study visit assessments should be
performed on the day of termination decision or on a separate visit.
2.9. Data analysis plan
Primary end point parameter(s) in the PK bridging studies with
exploratory PD assessments will be the assessment of the PK parameters
of enalapril (the parent compound) and enalaprilat (the active meta-
bolite). They will be estimated using a non-compartmental analysis
from the collected full PK proﬁles. This include the are under the curve
(AUC) within the dosing interval, Cmax, and tmax. Individual PK
parameters of AUC and Cmax will be adjusted to weight and dose (and/
or body surface area normalized dose) and then compared between the
diﬀerent age subsets using parametric statistical testing (e.g. ANOVA).
The primary endpoint in the follow-up safety study will be the ob-
served adverse events. The observed adverse events will be assessed
concerning their causal relationship with ODMT intake and presented
descriptively in relation to age and other covariates. AEs and ARs will
be coded according to the latest version of MedDRA. Preferred terms of
AE/ARs will be calculated as total and relative numbers and categor-
ized by severity, by causality and by dose level.
Secondary endpoints: Markers of the RAAS and NT-proBNP will be
calculated as arithmetic mean, standard deviation, median, 1st and 3rd
quartile, interquartile-range, minimum and maximum categorized by
age-group and by titration-level. Ordinal rating items of the accept-
ability and palatability assessment will be calculated as median,
minimum and maximum. Safety parameters (blood pressure and renal
function) will be analysed as individual absolute and relative change
from baseline (CFB).
Modelling and Simulation: In addition to the non-compartmental
analysis of the full PK proﬁles, population PK modelling will be per-
formed on all collected PK data from the start to the end of the study. A
covariate analysis will be performed to investigate sources of variability
of the resulted dose exposure relationship, and covariates shall include
the various patient characteristics collected such as age, weight, height,
disease score, etc.
3. Ethics and dissemination
Potential beneﬁts for children: Although few clinical studies have
been conducted in paediatric patients, enalapril is considered a ﬁrst-
line treatment for chronic heart failure in children [12]. There is cur-
rently no licensed formulation of enalapril available in Europe suitable
for use in children with heart failure, resulting in the administration of
extemporaneous oral preparations. This means that the actual dose
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received is often not known, as extemporaneous preparations tend to
have unknown bioavailability compared to the original product (ta-
blet). Also, the quality attributes (content, stability, etc.) of these pre-
parations are very variable. These clinical studies will contribute to
enabling the development of a novel clinically relevant age-appropriate
and safe enalapril formulation, with an improved method of adminis-
tration and ease of dosing without the need for a measuring device
compared to products currently available.
The few data currently available on the PK of enalapril in paediatric
patients have been generated using outdated assay techniques, and
hence the reliability of these data is questionable. The LENA PIP pro-
poses to conduct PK studies on a new paediatric enalapril product
(ODMT) in heart failure patients from birth to under 12 years utilising a
sensitive and selective assay (HPLC-MS) to enable the dose-exposure
relationship of enalapril (and its active metabolite enalaprilat) in pae-
diatric patients to be elucidated. Safety data and explorative PD data on
parameters of the RAAS will also be generated. The provision of an age-
appropriate enalapril product together with frequent supervision of the
treatment and safety parameters will be of beneﬁt for the participating
patients and will generate a huge beneﬁt for children with heart failure.
Potential risks for children: Enalapril is currently standard of care in
this population. The risks associated with the ODMT formulation of
enalapril are managed by the treating investigator and are minimal.
The additional risk of participation in the studies may be related to the
diﬀerence in formulation used (potentially better absorption and higher
blood levels), but the risk of overdosing is minimised by the careful up-
titration in the pharmacokinetic bridging studies and the option to
adapt the dose at any time in the safety follow-up study.
The risks of ODMT administration in young children are considered
to be low by EMA as presented in the EMA guideline on pharmaceutical
development of medicines for paediatric use as acceptability and
swallowability of 2mm placebo minitablets have been demonstrated in
over 500 children aged between 0 and 6 years without occurrence of
any problems, except coughing in two children, in both cases without
clinical relevance [27–30]. The enalapril ODMTs administered in these
studies will rapidly disperse in the mouth and thus the risk of choking/
aspiration is considered negligible [16]. This potential risk is further
mitigated by the method of administration, which includes the provi-
sion of a drink if required.
A small risk might be sensitivity to the excipients, however, the
selected excipients are commonly used and have acceptable safety
proﬁles. The titration phase and the ongoing option for dose adaptation
will allow for careful and closely monitored identiﬁcation of an in-
dividual optimal dose over time for the long-term therapy. The option
to administer a dispersion of ODMTs as the ﬁrst dose for very small
children (2.5 kg – max. 7 kg) further enhances the ﬂexibility of the in-
vestigators to handle the titration very carefully.
Additional risks will be related to blood sampling and are con-
sidered minimal, as the blood sampling schedule is designed to be in
accordance with the guideline “Ethical Considerations for Clinical
Trials on Medicinal Products Conducted with the Paediatric Population,
2008” by applying low volume assays as well as modelling and simu-
lation techniques. The volume of blood draws in paediatric patients of
diﬀerent age groups in these studies will be within the maximum ac-
ceptable volumes deﬁned in that guideline.
However, blood sampling is expected to be a burden for the study
patients and poses a great challenge on patient and parental consent at
time of recruitment and throughout the whole study period. More fre-
quent study visits may also form an obstacle on recruitment. A good
relationship and cooperation between patient, parents, treating physi-
cians and the study team is of the utmost importance.
Dissemination: Final clinical study reports presenting primary and
secondary outcomes and study performance in comparison to the plans
presented in the protocols will be prepared and all results and learning
from the studies will be published on conferences and in peer-reviewed
journals as well as to the patient population.
The Children's Heart Federation (CHF) will inform both lay people
and health professionals about the progress of the studies. Two plat-
forms will be used to share information about the studies' progress: (1)
Key CHD conferences and events such as the European Congenital Heart
Disease Organisation (ECHDO's) and the British Congenital Cardiac
Association (BCCA) annual general meetings; (2) Scheduled quarterly
meetings for the congenital heart disease networks requesting CHF's
attendance. CHF's on-going links with partner groups and its member-
ship of the UK National Council for Child Health and Wellbeing
(NCCHW) also oﬀer a platform and opportunity to share information
about the studies. Information from these events will be shared with lay
members in local communities.
4. Conclusion
These paediatric clinical studies will enable the characterisation of
PK of enalapril and its active metabolite enalaprilat in young children
treated for heart failure with a newly developed age-appropriate for-
mulation, orodispersible minitablets. The exploration of the dose to
blood level relationships will allow for age-appropriate dose re-
commendations of enalapril. Furthermore, a wide range of PD para-
meters in young children treated for heart failure will be evaluated and
the acceptability and palatability of enalapril ODMTs will be tested.
Eﬃcacy of enalapril for the treatment of heart failure will not be di-
rectly demonstrated, but further explored on the basis of the measured
pharmacodynamic parameters. The follow-up safety study will de-
monstrate the long-term safety of enalapril ODMTs in children with
heart failure and will collect additional information about PK and PD of
enalapril ODMTs. In the sub-study, metabolomics and pharmacoge-
netics will be evaluated in relation to enalapril PK and PD parameters,
improving the understanding of the underlying disease and the in-
dividual response to enalapril treatment.
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